Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder

Inebilizumab (Uplizna(®)) is a recently approved monoclonal antibody for use in adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody seropositive. Inebilizumab targets the B cell antigen CD19 and effectively depletes circulating B cells, thus suppressin...

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Tina, Blair, Hannah A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Adis Drug Evaluation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550749/
https://www.ncbi.nlm.nih.gov/pubmed/36070074
http://dx.doi.org/10.1007/s40263-022-00949-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550749/
https://www.ncbi.nlm.nih.gov/pubmed/36070074
http://dx.doi.org/10.1007/s40263-022-00949-7

Ejemplares similares